Nagendra K Chaturvedi

List of Publications by Year
in descending order

27	583	759233 12	610901 24
papers	citations	h-index	g-index

27	27	27	1190
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment. Diagnostics, 2022, 12, 61.	2.6	10
2	Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy. Cancer Letters, 2021, 499, 24-38.	7.2	9
3	Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. BMC Cancer, 2021, 21, 1061.	2.6	6
4	Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma. Cancers, 2020, 12, 2576.	3.7	12
5	A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Molecular Cancer Therapeutics, 2020, 19, 1351-1362.	4.1	10
6	Long non-coding RNA profiling of pediatric Medulloblastoma. BMC Medical Genomics, 2020, 13, 87.	1.5	15
7	Exosomes secreted under hypoxia enhance stemness in Ewingâ€™s sarcoma through miR-210 delivery. Oncotarget, 2020, 11, 3633-3645.	1.8	12
8	Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy. Biochemical and Biophysical Research Communications, 2019, 520, 250-256.	2.1	14
9	Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. BMC Cancer, 2019, 19, 1056.	2.6	22
10	A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. Leukemia and Lymphoma, 2019, 60, 1214-1223.	1.3	10
11	Suppression of STAT3 NH₂â€terminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via deâ€repression by microRNAâ€21. Molecular Carcinogenesis, 2018, 57, 536-548.	2.7	14
12	Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. Oncotarget, 2018, 9, 16619-16633.	1.8	35
13	Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. Leukemia and Lymphoma, 2016, 57, 2874-2889.	1.3	2
14	Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood, 2016, 127, 2310-2321.	1.4	23
15	Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan. Oncotarget, 2016, 7, 15215-15229.	1.8	16
16	Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease. Molecular Medicine, 2014, 20, 290-301.	4.4	59
17	Human Prostatic Acid Phosphatase: Structure, Function and Regulation. International Journal of Molecular Sciences, 2013, 14, 10438-10464.	4.1	65
18	Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-Îº B and mTOR Dual-Targeting Approach. Molecular Cancer Therapeutics, 2013, 12, 2006-2017.	4.1	27

#	Article	IF	Citations
19	Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e70352.	2.5	39
20	The Role Of PRDM1 and Its Interacting Proteins In The Pathogenesis Of Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2865-2865.	1.4	0
21	Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites. Leukemia and Lymphoma, 2012, 53, 2269-2278.	1.3	7
22	Retention and transmission of active transcription memory from progenitor to progeny cells via ligandâ€modulated transcription factors: elucidation of a concept by BIOPIT model. Cell Biology International, 2012, 36, 177-182.	3.0	8
23	Lymph nodeâ€induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolinâ€1. British Journal of Haematology, 2012, 158, 216-231.	2.5	34
24	Stromal Tumor Microenvironment in CLL: Regulation of Leukemic Progression. Blood, 2012, 120, 1781-1781.	1.4	0
25	Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Targeting NF-ÎºB and mTOR Signaling Pathways in Vitro and in Vivo. Blood, 2012, 120, 63-63.	1.4	4
26	Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Letters, 2011, 311, 177-186.	7.2	35
27	Intracellular localization and nucleocytoplasmic trafficking of steroid receptors: An overview. Molecular and Cellular Endocrinology, 2006, 246, 147-156.	3.2	95